SEINE BIO · PEPTIDE PROFILE
UBT251
GLP-1/GIP/glucagon triple agonist · China and global development
InvestigationalGet to know the name, understand the evidence, and prepare a more informed conversation.
What is UBT251?
Targets GLP-1, GIP and glucagon receptors. Novo Nordisk and The United Laboratories reported Chinese phase 2 results in March 2026. This is an emerging research program, not an established retail treatment.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of UBT251.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Overview
UBT251 is a development-stage peptide targeting GLP-1, GIP and glucagon receptors. United Biotechnology and Novo Nordisk are developing it for metabolic disease. The shared receptor description with other triple agonists is a useful starting point, but it does not make these distinct molecules interchangeable medicines or identical research products.
Community Use
No exact UBT251 profile from PeptideDosages or Peptidepedia was verified for this article. The community context is therefore a source gap, not a reason to borrow retatrutide’s protocol. A development code appearing on a marketplace does not establish identity, clinical validation or participation in the developer’s program.
Doses, Durations & Cycles
Published dosing regimens. Product-label and study regimens for education, not instructions for self-treatment. Product, indication and route matter.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | Separate 1, 3 and 6 mg arms; initiation/escalation not established from the abstract reviewed | Weekly | 12 weeks Break: No biohacking break established by this study | Controlled phase 1b human study Diabetes, Obesity and Metabolism 2026: phase 1a/1b |
| Subcutaneous | Separate targets 2, 4 or 6 mg; the two 4 mg groups began at 0.5 or 1 mg. Other starting doses not disclosed in this report. | Weekly | 24 weeks Break: No biohacking break established by this study | Developer-reported phase 2 study / ADA conference results United Laboratories: phase 2 report, June 2026 |
Important context: 1 and 3 mg are phase 1b study arms, not universal starting and average doses. The cited phase 1b and phase 2 studies include 6 mg; the proposed 5 mg maximum is unsupported.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The table documents separate human-study arms. A phase 1a/1b publication examined safety, pharmacokinetics and pharmacodynamics; later developer reports describe phase 2 regimens. These are assigned study exposures, not a self-use ladder, and trial numbers should not be turned into a universal wellness cycle.
Research Findings
The early human study and Novo Nordisk’s March 2026 update address different stages of evidence. The latter reports a Chinese type 2 diabetes trial with placebo and semaglutide comparison. A company top-line release is useful, but it is not the same as independent review of a full publication.
U.S. Approval & Access
UBT251 remains a research-development topic in the sources reviewed. Global licensing rights and a planned trial do not establish FDA marketing authorization, personal eligibility or availability through Seine Bio. The named sponsor determines enrollment and investigational supply; membership cannot bypass that process or guarantee a future medicine.
What It Does in the Body
The triple-agonist design combines incretin-related signaling with glucagon-receptor activity. The development question concerns the balance between metabolic effects and tolerability. Reliable patient-level onset, peak benefit and duration after stopping have not been established for routine care. Pharmacokinetic measurements alone would not prove sustained functional or health benefits.
Benefits & Reported Experiences
The developer reported improvements in glucose measures and body weight in a defined Chinese diabetes population. Those endpoints should remain connected to that trial and its comparator. They do not show that every person seeking weight loss will respond similarly, nor that an unofficial material delivers the same exposure.
Side Effects & Risks
The phase 1 study evaluates tolerability and the developer describes a profile consistent with other triple agonist trials. Longer follow-up, detailed adverse-event tables and treatment discontinuations remain important. “Consistent” is not a claim of no risk, and early studies cannot settle every uncommon or delayed safety question.
Delivery Options
The cited human programs use subcutaneous administration. Route, formulation and trial oversight are part of the studied intervention. No alternative consumer route is established here. This page does not translate study arms into administration instructions, preparation steps or a way to recreate an investigational medicine.
Product Quality & Storage
Verify the exact program, sponsor and investigational product before interpreting an access claim. A purity certificate or familiar development code does not confirm clinical equivalence. No general patient-use storage instructions were verified; a legitimate trial supplies its own controlled handling requirements, product accountability and adverse-event contacts.
Combinations & Interactions
UBT251’s three receptor targets are built into one designed molecule. Mixing separate metabolic drugs or adding peptides is not equivalent. No stacking schedule can be inferred from its mechanism or another triple agonist’s trial. A study protocol’s restrictions and the clinical team’s assessment govern permitted concurrent medicines.
Talking With Your Provider
A consultation can clarify your present metabolic health and which established options address it. If a research program is relevant, the provider can help you understand its actual criteria and limitations. An inquiry is an opportunity for evidence-based discussion, not a promise of UBT251, trial acceptance or special-access approval.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →